Study of serum interleukin 33 and heat shock protein 70in allergic disease
Abstract: Allergic and hypersensitivity reactions are the results of immune response to allergens; this response is mediated by IgE antibody specific to the allergen. Mast cells, basophiles are activated after IgE bindings, starting a serious of cellular and molecular events that results in the clinical manifestation of allergic diseases. Type I reactions underlie atopic disorders (eg, allergic asthma, rhinitis, urticaria). Type I reactions develop < 1 h after exposure to antigen. The present study was aimed to evaluate the levels of interleukin 33 and heat shock protein 70 in allergic disease. interleukin 33 and heat shock protein 70 were done for 73 patients with allergic disease (allergic asthma, allergic rhinitis, and urticaria) their age between (10-70) years and 15 healthy control their age between (16-54) years collected from Allergy Specialized Center in Baghdad /AL-Resafa, during the period from April 2014 to September 2014. A highly significantly (p?0.001) increased in the mean level of serum interleukin 33 in patients with, allergic asthma, rhinitis, and urticaria (42.01 ± 4.67 , 39.94 ± 6.07 , 27.49 ± 2.90 pg/ml) respectively as compared with healthy controls (18.73 ± 2.73 pg/ml) while the levels of shock protein 70 was increased significantly (P ? 0.05) only in asthmatic patients (32.51 ± 3.85 ng /ml), as compared with healthy control (15.94 ± 4.27 ng /ml). Allergic disease associated with increased of serum IL-33 while HSP70 increased only in asthmatic patients. From this we can deduce that elevation of IL-33 is associated with allergic disease and HSP70 is associated with allergic asthma and may be a marker of the disease severity and potential therapeutic targets.
[Amna N. Jassim, Suaad A. Brakhas, Abrar J. Hassan (2015); Study of serum interleukin 33 and heat shock protein 70in allergic disease Int. J. of Adv. Res. 3 (2). 0] (ISSN 2320-5407). www.journalijar.com
Share this article
Download Full PaperDownload PDF No. of Downloads: 13 | No. of Views: 11
This work is licensed under a Creative Commons Attribution 4.0 International License.